DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjects.

Author(s): Cleary JC, Karmazyn Y, Mogayzel PJ Jr, Laube BL

Affiliation(s): Eudowood Division of Pediatric Respiratory Sciences, The Johns Hopkins Medical Institutions, Park 316, Baltimore, MD 21287-2533, USA.

Publication date & source: 2008, Pulm Pharmacol Ther., 21(1):105-11. Epub 2007 Jan 25.

Publication type: Research Support, N.I.H., Extramural

Acute inhalations of beta 2-adrenergic receptor agonists increase mucociliary clearance (MCC). Less is known about the effect of long-term inhalations of these agents on MCC, or cough clearance (CC). We hypothesized that chronic inhalations of nebulized levalbuterol, the R-isomer of albuterol, would enhance MCC and/or CC in healthy subjects, compared to albuterol or placebo. This was a randomized, double-blind, placebo-controlled trial in ten healthy, adult subjects who inhaled nebulized levalbuterol (1.25mg), albuterol (2.5mg), or placebo for 7 days, three times daily. MCC and CC were measured 6-7h after the last dose of drug on the 7th day of treatment. These were quantified from gamma camera images of the lungs following inhalation of an aerosol containing the isotope (99m)technetium. Levalbuterol did not improve MCC or CC. MCC averaged (+/-SD) 12.3+/-8.3%, 9.2+/-4.7% and 10.0+/-9.6% with placebo, albuterol and levalbuterol, respectively. CC averaged 3.9+/-6.8%, 4.9+/-4.3% and 3.8+/-6.4% with placebo, albuterol and levalbuterol, respectively. These results indicate that chronic inhalations of nebulized levalbuterol for 1 week do not increase MCC or CC in healthy subjects, compared to albuterol or placebo.

Page last updated: 2008-03-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017